| Lindsay Elizabeth Kula, LCSW | |
|
200 N Choctaw Ave, El Reno, OK 73036-2624 | |
| (405) 262-3209 | |
| Not Available |
| Full Name | Lindsay Elizabeth Kula |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 200 N Choctaw Ave, El Reno, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609075084 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 4942 (Oklahoma) | Secondary |
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Entity Name | Psychplus |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215516950 PECOS PAC ID: 9234547548 Enrollment ID: O20210426000608 |
News Archive
Meridian Health has received CEO Cancer Gold Standard™ accreditation, recognizing the organization's commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.
As part of its mission to become the first critical access hospital in Mississippi to demonstrate meaningful use of electronic health record EHR) technology, North Sunflower Medical Center plans to deploy a suite of McKesson information technology solutions. The new systems will replace paper-based records and disparate technologies and address duplicate data entry challenges with communications capabilities designed to automate outdated manual processes and better coordinate care.
Leading Republicans — after proposing to gut Medicare — are still trying to pose as the program's saviors. How cynical can they get? At the recent Republican presidential debate in New Hampshire, Representative Michele Bachmann of Minnesota warned that health care reform will take $500 billion out of Medicare and harm "senior citizens who have the most to lose."
Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lindsay Elizabeth Kula, LCSW 209 Sw 146th St, Oklahoma City, OK 73170-7266 Ph: (405) 206-3790 | Lindsay Elizabeth Kula, LCSW 200 N Choctaw Ave, El Reno, OK 73036-2624 Ph: (405) 262-3209 |
News Archive
Meridian Health has received CEO Cancer Gold Standard™ accreditation, recognizing the organization's commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.
As part of its mission to become the first critical access hospital in Mississippi to demonstrate meaningful use of electronic health record EHR) technology, North Sunflower Medical Center plans to deploy a suite of McKesson information technology solutions. The new systems will replace paper-based records and disparate technologies and address duplicate data entry challenges with communications capabilities designed to automate outdated manual processes and better coordinate care.
Leading Republicans — after proposing to gut Medicare — are still trying to pose as the program's saviors. How cynical can they get? At the recent Republican presidential debate in New Hampshire, Representative Michele Bachmann of Minnesota warned that health care reform will take $500 billion out of Medicare and harm "senior citizens who have the most to lose."
Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.
› Verified 1 days ago